Cobomarsen - miRagen Therapeutics

Drug Profile

Cobomarsen - miRagen Therapeutics

Alternative Names: MRG-106

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator miRagen Therapeutics
  • Class Antifungals; Antineoplastics; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adult T-cell leukaemia-lymphoma; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Jun 2018 Preliminary efficacy data from a phase I trial in Adult T-cell leukaemia-lymphoma and Diffuse large B cell lymphoma released by miRagen Therapeutics
  • 01 Jun 2018 Safety and efficacy data from phase I trial in Cutaneous T-cell lymphoma presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018) (NCT02580552)
  • 09 May 2018 miRagen Therapeutics completes enrolment in a phase I trial for Cutaneous T-cell lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top